Ethics and Compliance – Vermont

Statutory Price Disclosure for Vermont Prescribers

Notice to Vermont Prescribers

Vermont law 33 V.S.A. § 2005a requires pharmaceutical marketers to disclose to Vermont doctors and other prescribers the prices of the drugs they market as well as the prices of others products in the same therapeutic class.

Price Information

The disclosed prices are derived from Average Wholesale Prices (AWP) as established and made available to the public by a third party publisher or as calculated from data made available to the public by a third party publisher. We are required to use these prices for the disclosure forms.

Other Products

Under Vermont law, “therapeutic class” is defined as the therapeutic class listed in the American Hospital Formulary Service Pharmacologic-Therapeutic Classification published by the American Society of Health System Pharmacists, available at https://www.ashp.org.  The listing of Other Products is not intended to imply that such other products are interchangeable with the marketed product. Please refer to each product’s FDA-approved label and indication for further information.

Disclosure Forms

Innoviva Specialty Therapeutics, Inc. has listed below these therapeutic class prices in Short Form and Long Form Disclosures as required under Vermont Law.  The statements that appear on the disclosure forms are required under the Vermont Attorney General’s Guide to Pharmaceutical Marketer Price Disclosure Law.

Marketed Products:

GIAPREZA® (angiotensin II) (Short Form) (Long Form)

XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use

ZEVTERA (ceftobiprole medocaril sodium for injection) (Short Form) (Long Form)

XERAVA® (eravacycline) for injection (Short Form) (Long Form)

 

Information for Vermont Prescribers of Prescription Drugs (Short Form)

GIAPREZA® (angiotensin II)

  • This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.
  • The prices listed below are Average Wholesale Prices (“AWP”) as established and made available to the public by a third-party publisher or as calculated from data made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
  • The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

Price Comparison: Marketed product and lowest dosage of other products in the same therapeutic class.*

Marketed Product

GIAPREZA® (angiotensin II) 2.5MG for injection                                                                $2,278.80 AWP

GIAPREZA® (angiotensin II) 0.5MG for injection                                                                $630.00 AWP

 

Other Products

N/A

 

*Prices shown are for the lowest dosage of each product. Products for multi-source products have been averaged. Multiple forms of the same product (e.g., tabs and caps) have been considered one product, and the prices have been averaged. Chewable forms of the product are not included.

For additional price comparison information, see [insert web address where long form is available]

 

Information for Vermont Prescribers of Prescription Drugs

GIAPREZA® (angiotensin II)

  • This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.
  • The prices listed below are Average Wholesale Prices (“AWP”) as established and made available to the public by a third-party publisher or as calculated from data made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
  • The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

 

Product Name Manufacturer NDC or UPC Pkg Size Pkg Unit
Marketed Product
GIAPREZA® (angiotensin II) Innoviva Specialty Therapeutics, Inc. 68547-0501-02 2.5MG for injection, available in a carton as a single dose vial $2,278.80 Non Pill Product
GIAPREZA® (angiotensin II) Innoviva Specialty Therapeutics, Inc. 68547-005-01 0.5MG for injection, available in a carton as a single dose vial $630.00 Non Pill Product
Other Products
N/A

Source: Redbook 2/1/26

 

Information for Vermont Prescribers of Prescription Drugs (Short Form)

XACDURO® (sulbactam for injection; durlobactam for injection)

  • This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.
  • The prices listed below are Average Wholesale Prices (“AWP”) as established and made available to the public by a third-party publisher or as calculated from data made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
  • The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

Price Comparison: Marketed product and lowest dosage of other products in the same therapeutic class.*

Marketed Product

XACDURO® (sulbactam for injection; durlobactam for injection)                               $630.00 AWP

 

Other Products

N/A

 

*Prices shown are for the lowest dosage of each product. Products for multi-source products have been averaged. Multiple forms of the same product (e.g., tabs and caps) have been considered one product, and the prices have been averaged. Chewable forms of the product are not included.

For additional price comparison information, see [insert web address where long form is available]

 

Information for Vermont Prescribers of Prescription Drugs

XACDURO® (sulbactam for injection; durlobactam for injection)

This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.

  • The prices listed below are Average Wholesale Prices (“AWP”) as established and made available to the public by a third-party publisher or as calculated from data made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
  • The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

 

Product Name Manufacturer NDC or UPC Pkg Size Pkg Unit
Marketed Product
XACDURO® (sulbactam for injection; durlobactam for injection) Innoviva Specialty Therapeutics, Inc. 68547-0111-10 0.5g-0.5g-1g co-packaged for intravenous use $630.00 Non Pill Product
Other Products
N/A

 

Source: Redbook 2/1/26

 

Information for Vermont Prescribers of Prescription Drugs (Short Form)

ZEVTERA (ceftobiprole medocaril sodium)

  • This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.
  • The prices listed below are Average Wholesale Prices (“AWP”) as established and made available to the public by a third-party publisher or as calculated from data made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
  • The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

Price Comparison: Marketed product and lowest dosage of other products in the same therapeutic class.*

Marketed Product

ZEVTERA (ceftobiprole medocaril sodium)                                                                        $2,820.00 AWP

 

Other Products

N/A

 

*Prices shown are for the lowest dosage of each product. Products for multi-source products have been averaged. Multiple forms of the same product (e.g., tabs and caps) have been considered one product, and the prices have been averaged. Chewable forms of the product are not included.

For additional price comparison information, see [insert web address where long form is available]

 

Information for Vermont Prescribers of Prescription Drugs

ZEVTERA (ceftobiprole medocaril sodium)

  • This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.
  • The prices listed below are Average Wholesale Prices (“AWP”) as established and made available to the public by a third-party publisher or as calculated from data made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
  • The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

 

Product Name Manufacturer NDC or UPC Pkg Size Pkg Unit
Marketed Product
ZEVTERA (ceftobiprole medocaril sodium), Innoviva Specialty Therapeutics, Inc. 68547-0578-10 Single Dose Vial contains 667 mg, available in a carton of 10 single dose vials $2,820.00 $282.00
Other Products
N/A

Source: Redbook 2/1/26

 

Information for Vermont Prescribers of Prescription Drugs (Short Form)

XERAVA®(eravacyline)

  • This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.
  • The prices listed below are Average Wholesale Prices (“AWP”) as established and made available to the public by a third-party publisher or as calculated from data made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
  • The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

Price Comparison: Marketed product and lowest dosage of other products in the same therapeutic class.*

Marketed Product

XERAVA® (eravacyline) for injection, 50 mg vial, available in a 12-vial carton            $1,050.00 AWP

XERAVA® (eravacycline) for injection, 100 mg vial, available in a 12-vial carton        $1,798.00 AWP

 

Other Products

N/A

 

*Prices shown are for the lowest dosage of each product. Products for multi-source products have been averaged. Multiple forms of the same product (e.g., tabs and caps) have been considered one product, and the prices have been averaged. Chewable forms of the product are not included.

For additional price comparison information, see [insert web address where long form is available]

 

Information for Vermont Prescribers of Prescription Drugs

XERAVA® (eravacyline)

  • This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.
  • The prices listed below are Average Wholesale Prices (“AWP”) as established and made available to the public by a third-party publisher or as calculated from data made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
  • The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

 

Product Name Manufacturer NDC or UPC Pkg Size Pkg Unit
Marketed Product
XERAVA® (eravacyline) Innoviva Specialty Therapeutics, Inc. 71773-050-12 50 mg vial, available in a 12-vial carton $1,050.00 $87.50
XERAVA® (eravacyline) Innoviva Specialty Therapeutics, Inc. 71773-100-12 100 mg vial, available in a 12-vial carton $1,798.80 $149.90
Other Products
N/A

Source: Redbook 2/1/26